COVID-19 studies for: C19 studies:  HC QHC Q Vitamin DVitamin D IvermectinIVM LY-CoVLY REGN-COV2REGN RemdesivirRMD
HC Q study #43
Source   PDF   Share   Tweet
See all 143 studies
5/28
Negative
Late treatment study
Kuderer et al., Lancet, June 20, 2020, doi:10.1016/S0140-6736(20)31187-9 (preprint 5/28) (Peer Reviewed)
Clinical impact of COVID-19 on patients with cancer (CCC19): a cohort study
Retrospective 928 cancer patients, showing HC Q OR 1.06 [0.51-2.20]. HC Q+AZ OR 2.93 [1.79-4.79]. The relative risks of different therapies suggest that the results are overly affected by confounding by indication. Authors note: HC Q+AZ might not be the cause of increased mortality, but instead these were given to patients with more severe COVID-19.
death, ↑134.2%, p<0.0001
(odds ratio converted to relative risk)
Source   PDF   Share   Tweet
See all 143 studies
Please send us corrections, updates, or comments.
Submit